Medical Teams

FJCU/NTHU/NTUST
Laser Diffraction-Based Flow Microchip for Rapid and Label-Free Tumor

Jem Kun Chen
jkchen@mail.ntust.edu.tw
https://mse.ntust.edu.tw/index.php

Company Introduction

We developed a rapid, user-friendly automatic cell counting system using diffraction chips and laser detection. Antibody-grafted microgratings capture target cells, causing detectable diffraction changes for accurate quantification within minutes. This technology enables sensitive and efficient cell or bacteria detection for diagnostic and research applications.

Solution / Technology Highlights

Medical Device

Market Opportunities

The system enables rapid, label-free CTC detection for esophageal cancer monitoring, offering a more sensitive, real-time alternative to imaging, with potential in precision medicine and broader oncology applications.

Business Model

The company operates a dual B2B and B2B2C model, selling test modules and consumables to institutions, and offering clinical testing services via partner labs with recurring revenue from service and consumables fees.

Timeline

。Automated System Development Completed
。High-Sensitivity Chip Platform Established
。Clinical Validation Conducted
。Ed-Value Quantification & Calibration Model Established
。In Situ CTC Culturing Demonstrated

Company Stage

Angle round
Clinical validation in esophageal and endometrial cancer patients (IRB approved), with 58 patient samples analyzed across various treatment stages.

Team Members

Jem-Kun Chen, Advisor at NTUST
Kuo, Yi-Hsien, Master's student at NTUST
Chou, Tsung-Yu, Master's student at NTUST
Chuang, Min-Wei, Master's student at NTUST

Smart hearing solution
Augmented Reality Hearing Impaired Assistive System

Ching Feng Liu
elleryqueenwtcen@gmail.com

Executive Summary

Smart Hearing Solutions is a multidisciplinary team developing advanced hearing technologies backed by clinical trial data. With in-house capabilities spanning chip systems, hardware, software, and algorithms, the team delivers integrated, clinically validated solutions for hearing impairment, bridging medical expertise and engineering innovation.

Solution / Technology Highlights

Augmented reality hearing assisted system

Market Opportunities

Smart Hearing Solutions addresses the growing demand for high-SNR, low-power audio processing in wearables, offering compact, AI-enhanced technologies ideal for hearing aids and voice-enabled devices in noisy, real-world environments.

Business Model

1. Chip System Module Sales
2. Commissioned Design and Manufacturing
3. Terminal Product Development

Timeline

。Completed development of multi-die heterogeneous integrated chip system, including self-developed algorithms and firmware drivers
。Developed ultra-low power circuit to drive a synchronized 10-microphone miniature array, suitable for integration into eyeglass devices

Company Stage

Angle round
preliminary clinical trials completed

Team Members

Chan-Chi Chang MD. PhD. , Attending Physician of the Department of Otolaryngology, National Cheng Kung University Hospital
Ching-Feng Liu MD.PhD., Associate Professor, Department of Electrical Engineering, Southern Taiwan University of Science and Technology
Ji-Jer Huang PhD. , Associate Professor, Department of Electrical Engineering, Southern Taiwan University of Science and Technology

Rich Health Biomedical
Smart Spasticity Management System

Guo Sheng Li
a6130197@gmail.com
https://www.facebook.com/profile.php?id=61573515927824

Company Introduction

Rich Health, a Chang Gung University startup, develops innovative rehab technologies. Its flagship Smart Spasticity Management System offers non-invasive, sensor-driven ankle spasticity assessment and treatment. Backed by patents, research, and awards, the device provides accurate, user-friendly, and affordable solutions for advancing precision rehabilitation care.

Solution / Technology Highlights

A passive ankle movement trainer

Market Opportunities

The system addresses unmet needs in spasticity care by offering non-invasive, data-driven assessment and therapy for neurological patients, with broad application across hospitals, care facilities, and home settings.

Business Model

Rich Health uses a B2B2C model targeting clinics, care facilities, and patients, generating revenue from device sales, contracts, and future software services, with a go-to-market strategy focused on hospital pilots, validation, and academic-industry partnerships for regional and global expansion.

Timeline

。Our technology has reached TRL 8, supported by two peer-reviewed clinical studies demonstrating its safety and effectiveness in treating spasticity in cerebral palsy and spinal cord injury patients.

Company Stage

Angle round
Plan to conduct Clinical Trial

Team Members

PI: Ya-Ju Chang
coPI: Hsiao-Lung Chan
KP: Guo-Sheng Li

DMolution Co. Ltd.
Smart Diabetic Foot Screening System

Tommy Liao
tommyliao@dmolution.com
https://www.dmolution.com/

Company Introduction

DMolution is revolutionizing diabetic foot care with FootHow™, an intelligent screening system that provides fast, accurate, and accessible evaluations. By enabling early detection and data-driven prevention, DMolution empowers healthcare providers and patients, aiming to reduce amputations and build a global ecosystem for proactive foot health.

Solution / Technology Highlights

Medical device with integrated AI system for automated diabetic foot screening

Market Opportunities

FootHow addresses a major gap in diabetic foot care by offering rapid, accessible screening in clinics and remote settings, enabling early intervention, reducing amputations, and expanding preventative care in underserved communities.

Business Model

DMolution partners with clinics through a leasing and profit-sharing model for its FootHow device, generating revenue via maintenance and per-report fees, while enabling decentralized, community-based diabetic foot screening to reduce amputations and healthcare costs.

Timeline

。Completed patent applications in both Taiwan and US
。Developed initial software prototype through partnership with Shike International
。 Received IRB approval for clinical validation at Chang Gung Memorial Hospital with 100 planned participants

Company Stage

Angle round
Plan to conduct Clinical Trial

Team Members

Yeh Ting-Ting (PI): Assistant Professor, Master Degree Program in Health and Long-term Care Industry, Chang Gung University
Huang Chao-Shan: Physician, Department of Metabolism, Chang Gung Memorial Hospital
Liao Miao-Yu: Student, Department of Physical Therapy, Chang Gung University
Hsu Yi-Feng: Student, Department of Physical Therapy, Chang Gung University
Chang Chia-Chih: Student, Department of Physical Therapy, Chang Gung University
Chen Yu-Hsuan: Student, Department of Physical Therapy, Chang Gung University

oncoMASTER
OCM-002: AI-Powered Solution Integrating Multi-Omics and Clinical Data to Predict Immunotherapy Response in Solid Tumors

Hoon Seong
hoon.seong@oncomaster.co.kr
https://www.onco-master.com

Company Introduction

OncoMASTER is a precision oncology company using AI to personalize cancer treatment. Originating from the K-MASTER project with over 10,000 patient datasets, it develops predictive models for drug response. Its flagship product, OCM-002, forecasts immunotherapy efficacy through advanced multi-omics data analysis.

Solution / Technology Highlights

AI-driven CDSS for drug response prediction using multi-omics data

Market Opportunities

OncoMASTER addresses growing demand for personalized cancer care by improving immunotherapy precision through multi-omics AI. With ongoing PoC trials and Asia’s largest cancer cohort, it offers strategic value to pharma partners seeking real-world, AI-driven oncology insights.

Business Model

1. Development, regulatory approval, and commercialization of OCM-002 as a SaMD.
2. Joint development of AI models that predict therapeutic response tailored to pharmaceutical pipelines.
3. Data collaboration leveraging OncoMASTER’s proprietary cohort, public datasets, and partner-supplied data to generate novel therapeutic insights.

Timeline

。Developed and validated a prototype model using over 700 real-world Korean cancer patients treated with immune checkpoint inhibitors
。Patents filed for core prediction algorithm in colorectal and gastric cancers
。Clinically relevant prediction unlike existing immune activation scores

Company Stage

Angle round
Developed and validated a prototype model, digital pathology model (H&E slide-based) currently under

Team Members

Woo Young Jang, MD, PhD – CEO
Yoonji Choi, MD, PhD – CMO
Kyung-ha (Jason) Sa, PhD – CTO
Hoon Seong, Pharmacist, MBA – CBO

GrOwnValve GmbH
GrOwnValve

Axel Mewes
a.mewes@grownvalve.de
https://www.grownvalve.com/

Executive Summary

GrOwnValve is a groundbreaking, personalized biological heart valve grown within the patient, designed for lifelong use without medication. Tailored via 3D technology, it eliminates the need for multiple surgeries, enhancing quality of life for children and adults while reducing burden on families and healthcare systems.

Solution / Technology Highlights

3D rapid prototyping, Tissue remodeling, Minimally invasive heart valve replacement procedure, bioresorbable scaffold (Stent)

Market Opportunities

GrOwnValve targets a €9.89B adult heart valve market and an underserved €2.4B pediatric segment, aiming for €300M+ in combined market share by 2026 through hospital partnerships, cost-saving benefits, and disruptive single-surgery valve technology.

Business Model

GrOwnValve estimates that it will achieve a 10% market share in the adult market (€15.2M) and a 30% market share in the children market (€285.5M) in 2026. After clinical trials, the company's valuation will reach €22M by the end of 2024, with an annual revenue potential of €29.9M.

Timeline

。First in Human
。Long-Term Follow-Up
。ISO Certification
。Successful Pre-Clinic tests

Company Stage

Angle round
Successful Pre-Clinic tests, the first human implant has been completed and the first phase of clinical trials is currently underway.

Team Members

Schmitt, Boris, CEO, MD, PhD/ Pediatric Cardiology
Baumbach, Hardy/ CMO
Rieck, Benjamin/ COO, Head of General Administration
Warnack, Boris/ CTO, Head of R&D

miRacles™
miRaclesdx - a softer side to oral cancer detection

Nham Tran
nham.tran@uts.edu.au

Executive Summary

miRacles™ is a non-invasive, blood-based diagnostic tool for early oral cancer detection, using a proprietary microRNA biomarker panel with qPCR analysis. Delivering results in 24 hours, it enables timely intervention, improves survival rates, and reduces healthcare costs. Validated in global cohorts, it redefines the oral cancer care pathway.

Solution / Technology Highlights

Oral cancer blood test

Market Opportunities

miRacles™ addresses the critical need for early oral cancer detection with a non-invasive, blood-based test, enabling timely intervention, reducing treatment burden, lowering costs, and transforming current late-stage diagnostic practices.

Business Model

We will commercialize a miRNA-based blood test for early oral cancer through our pathology laboratory to conduct extensive screening of high-risk groups, achieve early diagnosis, improve treatment outcomes, and reduce medical costs in Taiwan and other countries.

Timeline

。Discovered over 200 serum microRNAs that were different in people with oral cancer compared to healthy individuals
。Focused on 10 key microRNAs that seemed to be the best at detecting oral cancer

Company Stage

Angle round
Currently undergoing cohort validation in Australia and Taiwan.

Team Members

Nham Tran (UTS)
Sam Khoury (CMRI)
Michael Wallach (CIMA)